VERACYTE, INC. (VCYT) Q3 2025 10-Q Quarterly Report
VERACYTE, INC. (VCYT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
VERACYTE, INC. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: Impact of 2025 US federal government shutdown on operations and macroeconomic volatility, including currency fluctuations and regional conflicts (Russia-Ukraine, Israel)
- • Updated risk: Restructuring and deconsolidation of Veracyte SAS in August 2025 causing $20.5M impairment and decline in biopharmaceutical revenue by 74% YoY Q3
VERACYTE, INC. Q3 2025 Quarterly FinancialsXBRL
Revenue
$132M
▲ +13.8% YoY▲ +1.3% QoQ
Net Income
$19M
▲ +26.3% YoY▲ +2052.8% QoQ
Gross Margin
69.2%
▲ +103bp YoY▲ +25bp QoQ
Operating Margin
17.4%
▲ +703bp YoY▲ +2145bp QoQ
Net Margin
14.5%
▲ +143bp YoY▲ +1526bp QoQ
ROE
1.5%
Total Assets
$1.4B
EPS (Diluted)
$0.24
▲ +20.0% YoY▲ +2500.0% QoQ
Operating Cash Flow
$45M
▲ +49.4% YoY▲ +33.2% QoQ
Source: XBRL data from VERACYTE, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on VERACYTE, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.